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Abstract
Objective: The purpose of this study was to investigate the course of autistic symptoms, using a quantitative measure of core
autistic traits, among risperidone-treated children who participated in a 10 year life course longitudinal study.
Methods: Parents completed surveys of intervention history, as well as serial symptom severity measurements using the
Social Responsiveness Scale (SRS), on their autism spectrum disorder (ASD)-affected children. Fifty participants (out of a
total of 184 with full intervention histories) were reported to have been treated with risperidone during the course of the study.
Serial SRS scores during risperidone treatment were available for a majority of children whose parents reported a positive
effect from risperidone.
Results: Two thirds of risperidone-treated children (n = 33) were reported by parents to have improved by taking the
medication, with the principal effects described being that children were calmer, better focused, and less aggressive. SRS
scores of children reported to have responded positively to risperidone did not improve over time.
Conclusions: Risperidone’s beneficial effect on aggression and other elements of adaptive functioning were not necessarily
accompanied by reduction in core ASD symptoms, as serially assessed by the same caregivers who reported improvement in
their children. These results reflect the distinction between reduction in core symptom burden and improvement in adaptive
functioning. Given the cumulative risks of atypical neuroleptics, the findings underscore the importance of periodic re-
evaluation of medication benefit for children with ASD receiving neuroleptic treatment.
Introduction
Children with autism spectrum disorder (ASD) experi-ence impairment caused by core symptoms of social com-
municative impairment and restricted repetitive behaviors, as well
as a high incidence of irritability, aggression, and hyperactivity.
Optimal management of ASDs involves targeting primary neuro-
developmental deficits as well as associated maladaptive behaviors,
generally via a comprehensive approach including pharmacother-
apy and behavioral therapies, as well as developmental, educa-
tional, and social supports (Scahill et al. 2012).
Although the prevalence of ASD continues to rise, with the latest
estimate at 1 in 68 children affected (Centers for Disease Control
and Prevention 2012), United States Food and Drug Administration
(FDA)-approved pharmacotherapies for ASD remain limited. Only
risperidone and aripiprazole have FDA approval for irritability and
aggression associated with ASDs, and neither is indicated for core
ASD symptoms. Nonetheless, given the disability incurred by core
ASD symptoms, several investigations have probed whether
these medications, in particular risperidone, may improve social-
communicative function, repetitive behavior, or restriction in range
of interests.
The literature describing risperidone’s impact on core charac-
teristics of ASDs has been mixed. Within the small number of
randomized, placebo-controlled trials, several support improve-
ments in overall ASD severity (Luby et al. 2006; Nagaraj et al.
2006), as well as specific primary ASD symptoms including so-
cialization (Shea et al. 2004; Nagaraj et al. 2006; Pandina et al.
2007), language or communication (Shea et al. 2004; Nagaraj et al.
2006), and stereotyped, repetitive behaviors (Shea et al., 2004;
Nagaraj et al. 2006). Open label trials (Zuddas et al. 2000; Williams
et al. 2006; Gencer et al. 2008) and naturalistic studies (Masi et al.
2003; Capone et al., 2008) also support risperidone’s ability to
improve social functioning and autistic severity, and one controlled
blinded study suggested that this effect was specific to risperidone
versus the typical antipsychotic haloperidol (Miral et al. 2008).
However, the largest randomized placebo-controlled trial of ris-
peridone, Research Units on Pediatric Psychopharmacology
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Network, failed to show a benefit of risperidone on core ASD
symptoms after 8 weeks (McDougle et al. 2005), and systematic
reviews highlighting the more rigorously designed studies report
the best evidence for improving irritability, rather than core ASD
symptoms, with one review noting moderate evidence for ame-
lioration of stereotyped behaviors but not social or communicative
function (McPheeters et al. 2011).
Although the collective database continues to grow, treatment
studies of risperidone in ASD share common limitations in their
ability to address whether risperidone can promote sustained ben-
efits in social-communicative competence and restricted, repetitive
behaviors. These limitations include the brevity of the treatment
trials, an important consideration given that some studies have
noted slower improvement in social function versus disruptive
behavior (Zuddas et al. 2000), and study designs in which core
characteristics of ASD are secondary end-points. Because the
largest trials selected for children with elevated irritability and
aggression (McCracken et al. 2002), the findings related to ris-
peridone’s effects on core symptoms may be less generalizable to
more heterogeneous clinical populations with ASD. In studies that
have examined effects on social deficits, the instruments used often
broadly characterized social function, rather than providing sensi-
tive quantitative measurements of core ASD symptoms (Shea et al.,
2004; Pandina et al. 2007; Scahill et al. 2013). Although the evi-
dence of risperidone’s efficacy for irritability in ASD is well es-
tablished, knowing its impact on primary autistic impairment in
children could be critical for treatment planning.
To investigate whether core features of autism improve over
time in children taking risperidone, we capitalized on the avail-
ability of data from a life course longitudinal study involving a
relatively unselected sample of children affected by ASD, whose
parents provided serial measures of autistic symptom severity and
retrospective histories of the interventions their children had re-
ceived. This naturalistic, longitudinal approach minimized the
potential for detection bias, as parental reports were not contingent
on treatment with risperidone, and facilitated observation of
treatment responses over many months to years. We examined
whether enduring use and parental report of a positive effect from
risperidone over the course of the study was associated with a
decline in symptom burden, as measured serially using the Social




A total of 235 families actively enrolled in the Autistic Traits
Life Course and Genetic Structure study (Constantino et al. 2009),
in which 184 parents provided retrospective summaries of inter-
ventions with their children. Participants were recruited from the
psychiatry practice of the senior author ( J.N.C.) and through public
recruitment efforts starting in 2002. All ASD diagnoses (n= 184)
were made by a physician, and confirmed using the Autism Diag-
nostic Interview Revised and/or the Autism Diagnostic Observa-
tion Scale. Parents reported that 50 of the participants with ASD
had undergone treatment with risperidone, and among those de-
scribed as responding positively to risperidone, 23 had serial SRS
measurements that were highly informative with respect to the
effect of risperidone (see Data analysis section). Selected sample
characteristics are provided in Table 1.
Measures
The SRS is an extensively validated quantitative trait measure
of social-communicative and restricted/repetitive behavior defi-
cits referable to core ASD symptoms, in which informants base
their ratings on cumulative observations of the subject in the
subject’s natural social settings (Constantino et al. 2000, Con-
stantino and Gruber 2012). Scores are continuously distributed
across the entire population, exhibit a unitary factor structure in
cross-sectional research (Constantino et al. 2004), and are largely
independent of intelligence quotient (IQ) among verbal ASD
subjects (Constantino et al. 2003), such that total scores index
quantitative variations in the severity of autistic impairment.
Higher scores correspond to greater impairment, and distinguish
children with ASD from those with other psychiatric conditions.
Subscale scores on the SRS 1) describe domains of core autistic
symptoms (social awareness, social cognition, social communi-
cation, social motivation, and mannerisms) that may be differ-
entially affected by a given treatment; and 2) relate to the
Diagnostic and Statistical Manual of Mental Disorders (DSM-V)
criterion domains for a diagnosis of ASD (American Psychiatric
Association 2013; Frazier et al. 2014). Parents completed serial
ratings using the SRS, typically annually, as a primary element of
data collection for the longitudinal study. Serial teachers SRS
Table 1. Participant Characteristics According to Medication Use
Risperidone (n = 23) Other medication (n= 78) Medication-free (n= 56)
Gender (% male) 95.7% 85.9% 94.6%
Age at initial SRS (years) 5.09 (2.87)* 7.08 (3.87) 5.59 (3.22)
Initial Parent SRS score 104.22 (19.79) 97.25 (30.82) 98.28 (30.03)
Initial Teacher SRS score 102.48 (31.55) 88.77 (33.00) 90.13 (33.05)
CBCL Internalizing T-Score 63.21 (9.00) 61.42 (10.21) 60.89 (10.20)
CBCL Externalizing T-Score 64.00 (10.52)* ** 57.16 (11.07) 54.75 (12.33)
CBCL Total T-Score 67.47 (8.35)** 62.24 (10.28) 60.36 (10.61)
IQ Score 70.94 (21.37) 85.77 (25.26) 87.00 (31.53)
Risperidone dose (mg/day) 2.25 (1.62) n/a n/a
Risperidone duration (months) 52.84 (33.74) n/a n/a
Total number of psychotropic medication trials 3.87 (2.58) 3.50 (3.13) n/a
Participants classified as ‘‘medication free’’ received no medication for a minimum of 3 years. All numbers with the exception of gender reported as
means with standard deviations in parentheses. No trend-level or significant differences were observed between treatment groups based on either parent or
teacher SRS scores. Asterisks indicate trend-level or significant differences for the risperidone group on post-hoc testing (*p = 0.053 for age and p = 0.065
for CBCL externalizing, risperidone vs. other-medicated group; **p £ 0.05, risperidone vs. unmedicated group). SRS, Social Responsiveness Scale;
CBCL, Child Behavior Checklist; IQ, intelligence quotient.
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scores, provided by different teachers over time, were also
available for a subset of participants.
Between years 8 and 9 of the study, parents completed a Sum-
mary of Life Course Interventions, (SLCI) (Supplementary Fig. 1)
(Supplementary material is available in the online article at http://
www.liebertonline.com/cap), a retrospective questionnaire re-
garding number, type, and duration of interventions, as well as the
overall effect of the treatment. Parental descriptions of treatment
effect of risperidone were reviewed (H.U.R.) and participants were
classified as corresponding to either 1) an overall positive effect or
2) an overall negative effect (including no benefit) from risper-
idone. Additional information regarding medication history, in-
cluding date and dosage, was obtained through either parent report
or physician record.
Parents also completed the Child Behavior Checklist (CBCL) at
study baseline only. The CBCL is an established parent report
measure for rating children’s behavior in a broad range of domains
linked to psychopathology (Achenbach 1991). Scores on this
measure include total severity, internalizing behavior, and exter-
nalizing behavior. T scores from 65 to 70 signify borderline clinical
severity; scores > 70 signify clinical severity.
Data analysis
Analyses of change in parent SRS score over the course of ris-
peridone treatment were conducted for those participants whose
parents reported a positive effect from risperidone. Twenty- three
participants (within the original group of 33 reported to respond
positively to risperidone) had SRS measurements whose timing
occurred such that scores were informative with respect to response
to risperidone. For 16 of these 23 subjects, a pretreatment SRS
baseline score, followed by at least one SRS score on treatment ( > 1
month time between scores, mean treatment duration 37.22– 24.79
months) was available. (We refer to these as ‘‘before-and-during
treatment’’ [BDT] subjects.) For a partially overlapping set of 19
subjects (mean treatment duration 62.94– 27.72 months), time-
rated changes in SRS score could be calculated from serial (on
average, yearly) SRS measurements obtained during treatment with
risperidone. (We hereafter refer to these as ‘‘serial measurement on
treatment’’ [SMT] subjects.) A subset of BDT subjects (n= 14) and
SMT subjects (n = 14) also had sufficient serial teacher SRS scores
for these analyses.
All analyses, including arithmetical calculations, Student’s t
tests, linear regression, and ANOVAs were calculated in SPSS
version 20.
Results
Characteristics of the ‘‘positive effect’’ subjects with longitu-
dinal SRS data informative to risperidone treatment response, as
well as subjects using other medications or no medications, are
reported in Table 1. Children taking risperidone did not signifi-
cantly differ in initial parent or teacher SRS score, IQ, internalizing
T score on the CBCL, or total number of psychotropic medica-
tion trials, from other groups. Age at initial SRS was signifi-
cantly different across groups (F = 4.300, df = 2, p = 0.015), and
the risperidone-treated group was younger than the ‘‘other medi-
cation’’ group ( p = 0.053). Significant and marginal group differ-
ences were observed for CBCL externalizing scores (F = 3.943,
df = 2, p = 0.023) and total scores (F = 2.963, df = 2, p = 0.056), re-
spectively. On post-hoc testing, CBCL externalizing scores were
higher in the risperidone group than in the unmedicated group
( p= 0.019) and the other-medicated group ( p = 0.065), with the
latter difference at the level of a trend. The risperidone group’s total
CBCL scores were in the borderline range for a clinical level of
severity, and significantly greater than those of the unmedicated
group only ( p= 0.05).
According to parental report on the SLCI, 33 of the 50 study
subjects who had received risperidone experienced positive effects
from the medication, whereas 17 experienced negative effects
(Supplementary Table 1)(Supplementary material is available in
the online article at http://www.liebertonline.com/cap). The most
commonly reported positive effects were reduced irritability, ag-
gression, and anxiety. Weight gain was by far the most common
negative effect. Mean duration of treatment for the negative effect
group was highly variable, but on average, it was lower than for the
positive effect group: 27.84– 29.17 versus 45.22 – 32.54 months
(t = 1.83, df= 46, p= 0.078).
Sixteen subjects reported to respond positively to risperidone had
parent SRS scores before and during treatment (BDT) with risper-
idone, allowing calculation of the change in score from a pretreat-
ment baseline. Parent SRS scores for this group increased (worsened)
by 4.19– 7.98 points/year (t = - 3.266, df= 15, p= 0.005) (Table 2).
Similarly, for the 19 who had serial parent measurements on treat-
ment (SMT) with risperidone, significant increases in SRS scores
were observed, specifically during the period of treatment with ris-
peridone, by 3.38– 6.01 points/year (t = - 3.112, df= 18, p= 0.006).
Both BDT and SMT groups also demonstrated increasing (worsen-
ing) scores on all five SRS subscales (Table 2).
Using linear regression, we examined whether baseline parent
SRS score or CBCL externalizing score predicted differences in
parent SRS scores during risperidone treatment, and neither had a
significant effect (F[2,15] = 0.189, p = 0.829). We note also an ab-
sence of age effects on SRS scores within the age range studied in
this clinical sample (Constantino and Gruber 2012).
To explore whether lack of improvement in parent SRS scores
was unique to risperidone responders, we compared changes in
SRS scores for groups on 1) other medications or 2) no medications
Table 2. Changes in SRS Scores among Children











in total SRS score,
points/year (SD)




Social Awareness 2.19 (3.02) 1.11 (2.77)
Social Cognition 0.94 (4.89) 1.11 (3.38)
Social Communication 6.13 (6.89) 3.84 (5.45)
Social Motivation 1.75 (4.51) 1.47 (5.66)
Autistic Mannerisms 3.88 (6.03) 3.00 (4.97)
BDT refers to subjects with SRS scores available ‘‘before-and-during
treatment’’ with risperidone. SMT refers to participants with SRS scores
available during treatment with risperidone (‘‘serial measurement on
treatment’’). Increases in scores signify worsening core symptoms. Means
are shown with standard deviations (SD) in parentheses.
**Indicates significant differences at p< 0.01.
SRS, Social Responsiveness Scale.
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over a 3 year time period. Unlike risperidone responders, these two
groups demonstrated mean improvements in SRS scores over
time, statistically significant for the latter group, with an effect size
of*0.56 (other medication: - 0.46 – 11.84 points/year [t = 0.899,
df = 70, p= 0.372]; no medication: - 6.64 – 8.72 points/year
[t = 4.989, df = 47, p = 0.000]).
We also repeated analyses of changes in SRS score using
available teacher SRS scores for the risperidone-treated group.
Baseline teacher and parent SRS scores were not significantly
different (Table 1; t= 0.234, df = 22, p = 0.817). Changes in serial
teacher SRS scores relative to risperidone treatment confirmed a
lack of significant improvement in core ASD symptoms for both the
BDT group (-.08 – 13.20 points/year (t= 0.322, df = 11, p = 0.753])
and the SMT group (1.20 – 16.81 points/year [t = 0-.528, df = 13,
p = 0.607]).
Discussion
We capitalized on a naturalistic, life course longitudinal study to
provide a unique, unbiased observation regarding the course of
autistic symptomatology in patients treated with risperidone over
a number of years. The data strongly suggest that although a
majority of parents of risperidone-treated children with ASD
noted improvement in their children’s condition when treated with
risperidone, the children’s core ASD symptoms, as serially mea-
sured by the SRS, failed to improve, and in fact subtly worsened
over time. This finding was surprising for several reasons. First,
because core features are so fundamental to ASD, parent-reported
improvement (and concomitant decision making by physicians to
incur risperidone-related risks over time), could be anticipated to
be associated with improvement in core symptomatology. Second,
other studies, including shorter-term randomized placebo-controlled
trials, have suggested improvements in social function during
treatment with risperidone. Third, our group previously observed
a cohort effect within the larger sample from which this study’s
subjects were drawn, in the direction of subtle but measurable
improvement over time in autistic impairment measured by the
SRS, rather than decline (Constantino et al. 2009).
It is worth noting that many of the children examined in this
study, which began recruitment in 2002, would have elicited a
practitioner’s recommendation for risperidone at a time when such
use would have been off-label. Hence, the sample may be weighted
toward relatively severe behaviors among children with ASDs, and
study participants on risperidone did in fact display higher exter-
nalizing and total scores on the CBCL, in spite of comparable initial
SRS scores. Here, in the context of a long-term longitudinal study,
we observed a lack of response of core symptom burden in the
setting of ‘‘real-world’’ clinical judgments about the risk–benefit
ratio of continuing treatment with risperidone.
Although the SLCI was retrospective, introducing possible re-
call bias, the benefits and side effects reported by parents conform
well to what is documented in the literature (Troost et al., 2005;
Jesner et al. 2007; Lemmon et al. 2011; McPheeters et al. 2011),
supporting the validity of parent report for this purpose. Only a
minority of parents reported improvements in symptoms related to
core features, with decreased rigidity/perseveration being more
commonly reported than improved social competency, a finding
also supported in reviews of current literature (McPheeters et al.
2011). We documented long treatment courses, on average nearly
28 months, for children whose parents reported predominantly
negative effects or no effect from risperidone. This observation
suggests that 1) improvement in either comorbid symptomatology
or adaptive functioning may be driving decision making regarding
duration of treatment; and 2) lack of a medication effect on core
symptoms may not always be well integrated in treatment decisions
for this challenging clinical population.
Our study has several unique strengths, including a naturalistic,
longitudinal design featuring a much longer time course (several
years) than standard clinical trials, and, therefore, occupying a
unique vantage point of observation on the effects of risperidone in
ASD. This lengthier period allows investigation of long-term out-
comes under circumstances that are generalizable to routine clinical
practice. The fact that the study is more highly representative of
families who viewed their children as benefiting from risperidone
presents an important opportunity to clarify the nature of perception
of improvement by parent report.
A limitation of the study is that participants were not random-
ized. Unmeasured differences within the risperidone-treated group,
in addition to the higher levels of externalizing measured on the
CBCL, could therefore have contributed to the lack of improve-
ment in core autistic symptoms. Therefore, although our findings
illustrate that risperidone treatment fails to reduce core symptom
burden, we cannot conclude that risperidone caused this outcome.
Lack of blinded ratings is another limitation, as treatment-related
expectations could have altered parents’ perceptions of their chil-
dren’s core symptoms. It is also possible that parents, particularly
those with children on risperidone, may have been less attentive to
core symptoms because of prioritizing management of disruptive
behaviors, in line with a prior treatment study (Arnold et al. 2003).
However, SRS scores from teachers corroborated the accuracy of
parental report for the risperidone-treated group, as baseline parent
and teacher SRS scores did not significantly differ and teacher SRS
scores similarly failed to improve over time. Further, given the
gradual improvement in SRS scores previously reported for the
larger longitudinal study sample (Constantino et al. 2009), parental
bias would have been expected to promote lower SRS scores, the
opposite of what we observed.
A separate issue is that the SRS, by virtue of being a trait-based,
heritable index of ASD severity, admittedly poses a stringent cri-
terion for detecting change in ASD symptomatology. Nevertheless,
core symptoms have been reported to improve in other treatment
studies using the SRS, which was able to ascertain nuanced in-
cremental changes in response to intervention (Klaiman et al. 2013;
Laugeson et al. 2014). Additional limitations of the study include a
relatively small sample size and the likelihood of children’s ex-
posure to other interventions while on risperidone. Replication in a
larger prospective cohort would be key for ascertaining whether
treatment with risperidone is a risk factor for sustained (albeit
subtle) worsening of core autistic symptomatology over time, and
how such worsening should weigh into cost–benefit ratios for the
initiation and continuation of treatment with risperidone in ASD-
affected children with aggression and/or irritability. Such con-
siderations should occur within the context of comprehensive
appraisal of the intervention options for children with ASD, including
combined treatments with medication and behavioral therapies,
which may better address core ASD symptoms, while minimizing
medication doses and potential side effects (Scahill et al. 2012).
Conclusions
We conclude that risperidone’s beneficial effect on aggression
and other elements of adaptive functioning in this longitudinal
study sample were not generally accompanied by reduction in core
ASD symptoms, as serially assessed by the same caregivers who
516 MARRUS ET AL.
reported improvement in their children. These results reflect the
important clinical distinction between reduction in core symptom
burden and improvement in adaptive functioning in the manage-
ment of ASD.
Clinical Significance
Given the lengthy course of risperidone treatment shown in this
life-course longitudinal study, periodic re-evaluation of medication
benefit for children with ASD receiving atypical neuroleptics is es-
sential for balancing the positive effects on adaptive functioning with
the cumulative risk of side effects. Clinicians should remain mindful
that improvement in core ASD symptoms, a goal of effective treat-
ment in ASD, is likely to require interventions beyond what can be
achieved by current FDA-approved pharmacotherapies.
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